Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 12/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | HRAS | P01112 | 3/20 | 0.34 |
| ▸ | ESR1 | P03372 | 3/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.34 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30464359 | 0.99 | ERBB2 (0.41) | ERBB2GRM4NAMPTHRASESR1 | |
| SCHEMBL19633039 | 0.98 | ERBB2 (0.40) | ERBB2GRM4NAMPTHRASESR1 | |
| Hydrochloric Acid SCHEMBL30464360 | 0.98 | ERBB2 (0.40) | ERBB2GRM4NAMPTHRASESR1 | |
| Hydrochloric Acid SCHEMBL30464368 | 0.89 | ERBB2 (0.38) | ERBB2GRM4HRASESR1ESR2 | |
| Hydrochloric Acid SCHEMBL19614868 | 0.89 | ERBB2 (0.38) | ERBB2GRM4HRASESR1ESR2 | |
| SCHEMBL19614901 | 0.87 | ERBB2 (0.42) | ERBB2GRM4HRASESR1ESR2 | |
| SCHEMBL19633089 | 0.87 | ERBB2 (0.43) | ERBB2GRM4 | |
| Hydrochloric Acid SCHEMBL19614842 | 0.85 | ERBB2 (0.40) | ERBB2GRM4NAMPTHRASESR1 | |
| SCHEMBL19632860 | 0.85 | ERBB2 (0.42) | ERBB2GRM4NAMPTAGPAT2 | |
| SCHEMBL19633019 | 0.84 | GRM4 (0.37) | ERBB2GRM4NAMPTAGPAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458069-B1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS INC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20190070194-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2019-03-07 | — | — | US | disclosed |
| US-20170333442-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170333442-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333442-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD79B, CLTB, FCGR3B | ERBB2 65/4885GRM4 830/4885NAMPT 3033/4885 |
| US-20190070194-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD79B, CLTB, FCGR3B | ERBB2 65/4885GRM4 830/4885NAMPT 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.